Athira Pharma, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Athira Pharma reports reduced net loss and operating expenses in Q3 2025, driven by a strategic shift to ATH-1105 development and a workforce reduction, while exploring strategic alternatives.
Athira Pharma reports reduced losses and operating expenses in Q2 2025, pivoting its R&D focus to ATH-1105 for ALS after its prior lead candidate failed to meet endpoints.
Athira Pharma announces Q1 2025 financial results, highlighting a net loss of $9.1 million and a strategic shift towards advancing the clinical development of ATH-1105 for neurodegenerative diseases.
Athira Pharma announced its Q3 2024 results, highlighted by a strategic shift to focus on ATH-1105 development and a workforce reduction, while pausing further development of fosgonimeton.
Athira Pharma has filed an amendment to its quarterly report to include previously omitted exhibits related to an employment offer and severance agreement with its Chief Medical Officer.
Athira Pharma's Q2 2024 report details financial results and provides updates on clinical trials, including the upcoming topline results for the LIFT-AD trial.
10-Q: Athira Pharma Reports Q1 2024 Results, Provides Update on Clinical Programs and Financial Position
Athira Pharma's Q1 2024 report details a net loss of $26.3 million, ongoing clinical trials for fosgonimeton, and sufficient cash to fund operations for at least the next 12 months.